Agenus Inc.

AGEN

US00847G8042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
6.5 ^USD	-20.25%		-30.18%	-60.74%

Apr. 12	Sector Update: Health Care Stocks Slipping Late Afternoon	MT
Apr. 12	Sector Update: Health Care	MT

Agenus Inc. Promotes Julie DeSander to Chief Business Officer

August 09, 2021 at 07:45 am EDT

Agenus Inc. announced that Julie DeSander promoted to Chief Business Officer.

Latest news about Agenus Inc.

Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 12	MT
Sector Update: Health Care	Apr. 12	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	Apr. 12	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	Apr. 12	CI
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	Apr. 05	MT
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	Mar. 18	MT
Transcript : Agenus Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	Mar. 14	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	Mar. 06	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	Feb. 15	MT
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	Feb. 11	CI
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer	Dec. 20	CI
Agenus Inc.(NasdaqCM:AGEN) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Agenus to Get $25 Million Milestone Payment From Bristol Myers Squibb Under AGEN1777 Licensing Deal	Dec. 11	MT
B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating	Nov. 09	MT
Transcript : Agenus Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (AGEN) AGENUS Posts Q3 Revenue $24.3M	Nov. 07	MT
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma	23-10-22	CI
Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas	23-10-21	CI
Transcript : Agenus Inc. - Special Call	23-10-18
Agenus Completes Patient Enrollment in Phase 2 Trial of Colorectal Cancer Therapy	23-10-10	MT
Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer	23-10-10	CI

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agenus Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.5 USD

Average target price

110 USD

Spread / Average Target

+1,592.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AGENUS INC.	-60.74%	136M
IQVIA HOLDINGS INC.	-0.10%	42.07B
LONZA GROUP AG	+48.32%	42.16B
MODERNA, INC.	+4.43%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+5.67%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-22.84%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.20%	12.11B
MEDPACE HOLDINGS, INC.	+26.30%	11.99B
UNITED THERAPEUTICS CORPORATION	+6.91%	11.06B

Other Biotechnology & Medical Research

Agenus Inc.

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Agenus Inc. Promotes Julie DeSander to Chief Business Officer

Latest news about Agenus Inc.

Chart Agenus Inc.

Company Profile

Income Statement Evolution

Ratings for Agenus Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research